Clinical Trial Update: AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on AK112 as neoadjuvant/adjuvant therapy for resectable non-small cell lung cancer; the study is currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: Resectable Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING